Latest Watson CEO Brief Rips Motive For FTC Subpoena

Law360, New York (June 4, 2010, 1:27 PM EDT) -- The Federal Trade Commission's bid to force Watson Pharmaceuticals Inc. CEO Paul M. Bisaro to testify in a competition probe into a patent settlement over the narcolepsy treatment Provigil is an extraordinary circumstance that warrants discovery, his lawyers have told a federal judge.

Bisaro's reply brief, lodged Thursday in the U.S. District Court for the District of Columbia, comes as the agency investigates whether a settlement Watson entered into to end Cephalon Inc.'s patent infringement lawsuit hindered the ability of other generics makers to enter into...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.